Depression is treatable. Most people are treated with talk therapy, medicine, or both, and brain stimulation is an option when those are not enough. Each card links to its source: a U.S. Food and Drug Administration (FDA) label or record, a National Institute of Mental Health (NIMH) page, or, for treatments still in clinical trials, the trial registry or company announcement.
Antidepressants and young people
Antidepressant labels carry an FDA boxed warning: in short-term studies, antidepressants increased suicidal thoughts and behaviors in children, teens, and young adults. Anyone starting a medicine or changing a dose should be watched closely, especially in the first few weeks. Never stop a medicine without talking to the prescriber.
Started a medicine and still not feeling well? Antidepressants usually take 4 to 8 weeks, and there are many next steps if the first one does not help. Source
citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac), paroxetine (Paxil, Pexeva), sertraline (Zoloft)
Depression in adults · some for young people
A widely used group of antidepressants.
Show details
duloxetine (Cymbalta), venlafaxine (Effexor XR), desvenlafaxine (Pristiq), levomilnacipran (Fetzima)
Depression in adults
Another widely used group of antidepressants.
Show details
Wellbutrin XL and other forms
Major depressive disorder · preventing seasonal depression
An antidepressant from a different chemical family (aminoketone) than SSRIs and SNRIs.
Show details
Remeron, Remeron SolTab
Major depressive disorder in adults
An antidepressant for which sleepiness is one of the most common effects.
Show details
for example amitriptyline, nortriptyline, imipramine, desipramine, doxepin
Depression
An older group of antidepressants. Maprotiline is the tetracyclic; the others FDA lists are tricyclics.
Show details
phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), selegiline patch (Emsam)
Depression
An older group of antidepressants with important food and medicine restrictions.
Show details
atypical antidepressants
Depression
Two older antidepressants that FDA groups as atypical antidepressants.
Show details
Trintellix
Major depressive disorder in adults
A newer antidepressant that acts on the serotonin system.
Show details
Viibryd
Major depressive disorder in adults
A newer antidepressant that acts on the serotonin system.
Show details
Exxua
Major depressive disorder in adults
A newer antidepressant taken as an extended-release tablet.
Show details
dextromethorphan + bupropion
Major depressive disorder in adults
A combination tablet of dextromethorphan (an N-methyl-D-aspartate, or NMDA, receptor antagonist) and bupropion.
Show details
Spravato
Treatment-resistant depression · depression with acute suicidal thoughts
A nasal spray form of esketamine, taken under supervision in a certified health care setting.
Show details
Zurzuvae
Postpartum depression in adults
The first pill approved specifically to treat postpartum depression.
Show details
Zulresso
Former postpartum depression treatment
A continuous IV infusion for postpartum depression given over 60 hours in a certified facility.
Show details
Abilify
Added to an antidepressant for major depressive disorder
An atypical antipsychotic that can be added when an antidepressant alone has not been enough.
Show details
Rexulti
Added to an antidepressant for major depressive disorder in adults
An atypical antipsychotic used as an add-on to antidepressants.
Show details
Seroquel XR
Added to an antidepressant for major depressive disorder · also bipolar depression
An atypical antipsychotic with several labeled uses.
Show details
Vraylar
Added to an antidepressant for major depressive disorder in adults · also bipolar I depression
An atypical antipsychotic with several labeled uses.
Show details
Caplyta
Added to an antidepressant for major depressive disorder in adults · also bipolar depression
An atypical antipsychotic taken as one capsule a day. It was already approved for schizophrenia and for bipolar I and II depression.
Show details
olanzapine + fluoxetine (Prozac)
Treatment-resistant depression · bipolar I depression
The antipsychotic olanzapine taken together with the SSRI fluoxetine.
Show details
brain stimulation under anesthesia
Severe depressive episodes · ages 13 and older
A brief electric current causes seizure activity in the brain while the person is under general anesthesia with a muscle relaxant. It has the longest history of use for depression.
Show details
magnetic pulses, no anesthesia
Treatment-resistant depression · adolescents 15 and older as an add-on
An electromagnetic coil held against the head sends repeated magnetic pulses to a mood-related brain area. It is done awake, in a clinic or office.
Show details
Stanford Accelerated Intelligent Neuromodulation Therapy, Magnus Neuromodulation System (Magnus Medical)
Adults with major depression when antidepressants have not helped enough
A faster form of rTMS. Magnetic resonance imaging (MRI) brain scans are used to find a personal target spot, then the whole course is packed into 5 days.
Show details
Flow FL-100 (Flow Neuroscience)
Moderate to severe major depression in adults 18 and older
A headset that sends a weak electrical current to a mood-related area at the front of the brain. It works with a phone app.
Show details
implanted device
Long-lasting, hard-to-treat depression in adults
A small device implanted in the chest sends electrical pulses through the vagus nerve in the neck.
Show details
cognitive behavioral therapy (CBT), interpersonal therapy (IPT), and others
Depression of all levels · in person or by telehealth
Working with a licensed mental health professional to learn new ways of thinking and behaving. CBT targets unhelpful thoughts and habits; IPT focuses on relationships and life events.
Show details
bright light box
Seasonal affective disorder, winter pattern
Sitting in front of a very bright light box to make up for less natural sunlight in darker months.
Show details
Rejoyn (Otsuka)
Adults 22 and older with major depression who take an antidepressant
A smartphone app with lessons and exercises based on cognitive behavioral therapy (CBT), prescribed alongside regular care.
Show details
Compass Pathways
Treatment-resistant depression in adults
A lab-made form of psilocybin, the active compound in "magic mushrooms", given in a clinic together with psychological support.
Show details
lysergide (lysergic acid diethylamide), formerly MM120 (Definium Therapeutics)
Major depressive disorder in adults
A dissolving tablet form of LSD, a psychedelic, being tested as a single supervised dose.
Show details
formerly CYB003 (Helus Pharma)
Added to an antidepressant for major depressive disorder
A modified, psilocybin-like psychedelic tested as two supervised doses added to an antidepressant.
Show details
Usona Institute, a nonprofit
Major depressive disorder in adults
A single dose of psilocybin with psychological support, tested against placebo.
Show details
Johnson & Johnson
Added to an antidepressant for major depression with insomnia symptoms
A daily pill that blocks orexin, a brain signal that keeps us awake, being tested for depression with sleep problems.
Show details
NBI-1065845, formerly TAK-653 (Neurocrine Biosciences)
Added to an antidepressant for major depressive disorder
A pill that boosts AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors, a type of glutamate receptor that helps brain cells signal to each other, tested as an add-on to antidepressants.
Show details
Lipocine
Severe postpartum depression
A pill form of brexanolone, the medicine that used to be given as a 60-hour IV infusion (Zulresso), designed as a 48-hour course at home.
Show details
Reunion Neuroscience
Postpartum depression
A psychedelic related to psilocybin, given as an injection under the skin. The company designed it for a shorter psychedelic experience than psilocybin or LSD.
Show details
mebufotenin (5-MeO-DMT), AtaiBeckley, being acquired by Lilly
Treatment-resistant depression
A nasal spray form of 5-MeO-DMT, a short-acting psychedelic, given during a clinic visit of about two hours.
Show details
5-MeO-DMT (GH Research)
Treatment-resistant depression
An inhaled form of 5-MeO-DMT, a short-acting psychedelic.
Show details
Sunosi (Axsome)
Major depression with excessive daytime sleepiness
A wake-promoting pill already sold as Sunosi for daytime sleepiness from narcolepsy or sleep apnea, now being tested for depression.
Show details
Xenon Pharmaceuticals
Major depressive disorder · bipolar depression
A daily pill that opens potassium channels to calm overactive brain cells, also being reviewed for epilepsy.
Show details
Medicine names and warnings come from FDA labels on DailyMed, FDA device and drug records, and FDA consumer pages. Cards marked In clinical trials cite the trial registry or the company's own announcement, and company plans can change. Status was checked on September 30, 2026. Labels change; check the linked source for the latest.
Everyday habits
Self-care steps NIMH suggests once treatment has started. They support recovery; they are not a substitute for diagnosis or care.
Talk with a health care provider before starting any supplement or making big changes.
Just 30 minutes a day of walking can boost your mood.
NIMH lists physical activity among the things that may help once treatment has started.
A helpful habit alongside treatment, not a replacement for it.
National Institute of Mental Health · DepressionKeep a regular bedtime and wake-up time, and eat regular, healthy meals.
Steady routines are part of the self-care NIMH recommends while depression treatment takes effect.
Big changes in sleep or appetite can be symptoms themselves. Mention them to the care team.
National Institute of Mental Health · DepressionTalk to people you trust about how you are feeling.
NIMH suggests connecting with people and doing things you used to enjoy, even when you do not feel like it, because they can improve mood.
If someone tells you they are thinking about suicide, do not keep it secret. Contact 988.
National Institute of Mental Health · DepressionSteer clear of substances that can make depression harder to treat.
Using alcohol or drugs more can be a sign of depression. NIMH advises avoiding alcohol, nicotine, and drugs, including medicines not prescribed for you.
If substance use is part of the picture, see the Substance Abuse and Mental Health Services Administration (SAMHSA) National Helpline on the Resources page.
National Institute of Mental Health · DepressionFDA has not approved any natural product for treating depression.
Some people report that vitamin D or St. John's wort helped, but research findings are inconsistent, and these products can interact with prescription medicines.
Do not use vitamin D, St. John's wort, or other supplements for depression without talking to a health care provider first.
National Institute of Mental Health · DepressionClinical trials
1,442 depression studies were recruiting on ClinicalTrials.gov as of September 30, 2026. Below are 54 of them: mostly Phase 2, 3, and 4 treatment studies with at least one site in the United States, picked to cover different kinds of depression and treatment.
Talk with your doctor before joining a trial
A listing here is not a recommendation. Studies test treatments that may not work or may have side effects, and each one has its own rules about who can join. Ask your doctor, or your child's doctor, whether a study fits, and keep taking current treatment unless your care team says otherwise. A research study is not emergency care: in a crisis, call or text 988.
Find a study near you
This opens ClinicalTrials.gov with recruiting depression studies already selected. Type your city or ZIP code in the Location box to see studies close to home.
Search recruiting depression studiesStudies run by NIMH at the National Institutes of Health (NIH) campus in Bethesda, Maryland
Adults with depressionChildren with depressionHow clinical trials work (NIMH)Major depression
Brief title: A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Official title: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide in Delaying Time to Relapse Compared With Placebo in Adult Participants With Major Depressive Disorder (RENEW-MDD 1)
Major depression
Brief title: Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Official title: A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
Older adults · Major depression
Brief title: Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Official title: A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-(Milligram) mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms
Older adults · Major depression
Brief title: A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
Official title: A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate Efficacy and Safety of Seltorexant as Monotherapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) and an Open-label Long-term Extension Treatment With Seltorexant
Major depression
Brief title: A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
Major depression
Brief title: Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Official title: A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Study of Solriamfetol in Subjects With Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Major depression
Brief title: Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Official title: A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Milsaperidone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Major depression
Brief title: A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Official title: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder
Bipolar depression
Brief title: A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Official title: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Bipolar depression · Children and teens
Brief title: Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lumateperone for the Treatment of Major Depressive Episodes (MDEs) Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) in Pediatric Patients Aged 10 to 17 Years
Bipolar depression · Children and teens
Brief title: A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder
Official title: A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in Pediatric Subjects (10 to 17 Years of Age) in the Treatment of Depressive Episodes Associated With Bipolar I Disorder
Major depression
Brief title: A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Official title: An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active Doses of CYB003 and Placebo in Eligible Participants With Major Depressive Disorder
Major depression
Brief title: A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
Official title: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Major Depressive Disorder - Ascend
Pregnancy and postpartum · Children and teens
Brief title: Brexanolone Lifting Outcomes Of Moms
Official title: A Randomized, Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral LPCN 1154A in Women With Postpartum Depression
Major depression
Brief title: A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Official title: A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Adults With Major Depressive Disorder (MDD), With or Without Anxious Distress
Major depression
Brief title: A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Major depression
Brief title: Study of ALTO-300 in MDD
Official title: A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder
Major depression
Brief title: A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Official title: A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder (MDD)
Children and teens · Suicidal thoughts · Major depression
Brief title: A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Official title: A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants With Acute Suicidal Ideation or Behavior
Major depression
Brief title: Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Official title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder
Bipolar depression
Brief title: ALTO-100 in Bipolar Disorder With Depression (BD-D)
Official title: A Randomized, Double-Blind, Placebo-Controlled Study Followed by Open-Label Treatment of ALTO-100 in Adults With Bipolar Disorder Currently Experiencing a Major Depressive Episode
Major depression
Brief title: A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
Official title: A Phase 2, Multicenter, 6-Week, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects With Major Depressive Disorder
Hard-to-treat depression
Brief title: ALTO-207 in Adults With Treatment-resistant Depression (TRD)
Official title: A Randomized, Double-blind, Placebo-controlled Trial of ALTO-207 in Adults With Treatment-resistant Depression
Major depression
Brief title: Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Official title: A Phase 2, Multicenter, Randomized, Double-blind Evaluation of the Efficacy and Safety of Oral GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder in Adults
Major depression
Brief title: A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Official title: Phase 2, Multicenter, Randomized, Double-Blind Evaluation of the Efficacy and Safety of Oral GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Hard-to-treat depression · Major depression
Brief title: ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Official title: A Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of ACP-211 Monotherapy in Adults With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Hard-to-treat depression · Major depression
Brief title: A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
Official title: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled Trial to Assess the Efficacy, Safety, and Tolerability of Repeated Doses of VLS-01 Buccal Film in Participants With Treatment Resistant Depression
Major depression
Brief title: A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
Official title: A Phase 2 Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder Receiving Pharmacological Therapy for Depression
Other depression
Brief title: PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
Official title: Comparative Effectiveness of Racemic Ketamine Versus Esketamine (Spravato®) for Depression
Hard-to-treat depression
Brief title: A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
Official title: A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
Major depression
Brief title: A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
Official title: A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms
Hard-to-treat depression · Major depression
Brief title: Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
Official title: A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans
Hard-to-treat depression · Major depression
Brief title: Biomarker-guided rTMS for Treatment Resistant Depression
Official title: Efficacy of Biomarker-guided rTMS for Treatment Resistant Depression
Hard-to-treat depression · Older adults · Major depression
Brief title: Lumateperone for Late-Life Depression
Official title: Lumateperone for Late-Life Depression
Children and teens
Brief title: Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth
Official title: Prefrontal Glutamatergic Modulation by N-acetylcysteine and Mindfulness-based Cognitive Therapy for Mild Depression in Youth
Hard-to-treat depression
Brief title: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Official title: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Major depression
Brief title: Nebulized Ketamine for the Treatment of Major Depressive Disorder
Official title: Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting: A Midazolam-controlled Randomized Controlled Trial
With another health condition
Brief title: Creatine for Depressed Male and Female Methamphetamine Users
Official title: An Open-Label Pilot Study of Creatine for Depressed Male and Female Methamphetamine Users
Hard-to-treat depression · Major depression
Brief title: Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Official title: Treatment ResistAnt Depression Subcallosal CingulatE Network DBS
Pregnancy and postpartum
Brief title: Sleep to Reduce Incident Depression Effectively in Peripartum
Official title: Sleep to Reduce Incident Depression Effectively in Peripartum
Suicidal thoughts
Brief title: Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression
Official title: Implementing Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression Among At-Risk Rural and Urban Veterans
Children and teens · Suicidal thoughts
Brief title: Clinical Trial for Integrated Care to Help At Risk Teen (iCHART) Intervention
Official title: The Center for Enhancing Triage and Utilization for Depression and Emergent Suicidality (ETUDES) in Pediatric Primary Care-iCHART RCT
With another health condition
Brief title: Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)
Official title: Home-Based tDCS for Depression in Multiple Sclerosis: A Randomized Sham-Controlled Trial
With another health condition
Brief title: Inflammation and Depression in People With HIV
Official title: The Role of Inflammation in Central Nervous System (CNS) Mechanisms of Anhedonia and Psychomotor Slowing in Depressed People With HIV
With another health condition · Major depression
Brief title: Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
Official title: In Vivo Targeting of Neuroactive Steroid and Immune Networks for Depression in People Living With HIV
With another health condition · Major depression
Brief title: Imaging Depression in Parkinson's Disease
Official title: Identifying the Neural Basis of Depression in Parkinson's Disease
Older adults
Brief title: Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression
Official title: Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression
Older adults · With another health condition
Brief title: A Digital Intervention for Post-Stroke Depression and Executive Dysfunction
Official title: Efficacy and Target Engagement of a Digital Intervention to Improve Depression and Executive Dysfunction After Stroke
Older adults
Brief title: Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II
Official title: Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II
Bipolar depression · Suicidal thoughts
Brief title: Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
Official title: Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
Pregnancy and postpartum
Brief title: The ROSE Scale-up Study: Informing a Decision About ROSE as Universal PPD Prevention
Official title: The ROSE Scale-up Study: Informing a Decision About ROSE as Universal Postpartum Depression Prevention
Pregnancy and postpartum
Brief title: SAINT in Postpartum Depression (PPD)
Official title: A Randomized Controlled Multi-site Trial Evaluating SAINT for Postpartum Depression
Pregnancy and postpartum
Brief title: Implementation of a Clinical Decision Support Tool for Postpartum Depression
Official title: Implementation of a Clinical Decision Support Tool for Postpartum Depression
Pregnancy and postpartum · Children and teens
Brief title: ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
Official title: ICBT for Maternal Depression: Community Implementation in Head Start
Showing 54 of 54 studies · data from the ClinicalTrials.gov public data service, fetched September 30, 2026
See all 1,442 on ClinicalTrials.gov →Recruiting, interventional Phase 2, 3, or 4 studies (plus a few no-phase therapy and device studies) whose title and listed conditions are about depression and that have at least one US site. Up to 54 are shown, balanced across depression types and treatment kinds (at most 2 per main intervention), then ranked by phase, number of US sites, and size. Phase 1 safety studies and studies with no US site are left out here but appear on ClinicalTrials.gov. Study details change often; always check the study page and contact the study team to confirm who can join. This site does not enroll anyone.
